Viewing Study NCT06479135

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:13 PM
Ignite Modification Date: 2026-02-22 @ 5:09 PM
Study NCT ID: NCT06479135
Status: RECRUITING
Last Update Posted: 2025-09-25
First Post: 2024-06-21
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Sponsor: Kartos Therapeutics, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Myelofibrosis View
None Post-PV MF View
None Post-ET Myelofibrosis View
None Primary Myelofibrosis View
None MF View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Navtemadlin View
None KRT-232 View
None Ruxolitinib View
None POIESIS View
None TP53 View
None Suboptimal response View
None Sub-optimal response View